Would you like to know how many people have read this article? Or how reputable the author is? Simply
sign up for a Advocate premium membership and you'll automatically see this data on every article. Plus a lot more, too.
Pfizer Inc announced in a press release today that the U.S. Food and Drug Administration has approved SelzentryTM (maraviroc) tablets, the first in a new class of oral HIV medicines in more than 10 years.
What is interesting about this announcement is that it comes after an earlier delay of approval, shortly after an internal Pfizer whistleblower alleged Pfizer had illegally premarketed maraviroc.
And even more interesting is that this approval comes only a few days after it was revealed on BrandweekNRX that three executives in Pfizer's HIV division had been terminated.
All of this could, of course, be a highly unusual string of coincidences.
If it is not . . . continue reading here.